open access to scientific and medical research

Back to Journals » Biologics: Targets and Therapy » Volume 6

Original Research

Noteworthy comment: This study demonstrates that halving the dose of adalimumab used for the treatment of psoriatic arthritis (PsA) maintains drug efficacy, reduces drug exposure risks and affords cost savings. Clinical remission was achieved in a high percentage of patients with early PsA. In contrast to patients with rheumatoid arthitis, a high proportion of PsA patients maintained remission over a long-term follow-up.

Highly-accessed

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Total article views		HTML views	PDF downloads	Totals
15,868	Dovepress*	13,359+	2,011	15,370
	PubMed Central*	2,509	920	3,429
	Totals	15,868	2,931	18,799
*Since 12 July 2012 +Since July 2016

View citations on PubMed Central and Google Scholar